News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – September

AR-13324-CS208 Japan Phase 2 Study Topline Results

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe
- Roclanda ® Achieves Non-Inferiority to Ganfort ® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - DURHAM, N.C. --(BUSINESS WIRE)--Sep. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 8, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
TOP